Evidence map›Paper›PMID 41702955›Full record

ArticleNature communications2026

R-loop editing by DNA cytosine deaminase APOBEC3B modulates the activity of oestrogen receptor enhancers.

Chi Zhang, Yu-Jing Lu, Bingjie Chen, Zhiyan Bai, Qiaoxi Zeng, Alexia Hervieu, Marco P Licciardello, Konstantinos Mitsopoulos, Bissan Al-Lazikani, Marcello Tortorici and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Collapsing retroviruses for efficient delivery of viro-toxic cargoes.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chi ZhangCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.ORCID http://orcid.org/0000-0002-9188-6307
Yu-Jing Lu *Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.ORCID http://orcid.org/0000-0003-2494-843X
Bingjie Chen *GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID http://orcid.org/0000-0001-7689-2146
Zhiyan BaiKey Laboratory of Synthetic Biology, Ministry of Agriculture and Rural Affairs, Advanced Synthetic Biology Institute at Hohhot, Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen, China.
Qiaoxi ZengShanghai Institute of Biological Products, Shanghai, China.
Alexia HervieuCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.ORCID http://orcid.org/0000-0002-8061-6678
Marco P LicciardelloCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.
Konstantinos MitsopoulosCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.
Bissan Al-LazikaniCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.
Marcello TortoriciCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom.
Olivia W RossaneseCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom. olivia.rossanese@icr.ac.uk.ORCID http://orcid.org/0000-0002-1262-9522
Paul WorkmanCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom. paul.workman@icr.ac.uk.ORCID http://orcid.org/0000-0003-1659-3034
Paul A ClarkeCentre for Cancer Drug Discovery, Division of Cancer Therapeutics, the Institute of Cancer Research, London, United Kingdom. paul.clarke@icr.ac.uk.ORCID http://orcid.org/0000-0001-9342-1290

Funding

Cancer Research UK (CRUK) C2739/A22897Cancer Research UK (CRUK) C309/A11566Wellcome Trust (Wellcome) 094885/Z/10/ZWellcome Trust (Wellcome) 212969/Z/18/Z
6 · The paper itself

Abstract

Oestrogen receptor (ER) activation leads to the formation of DNA double strand breaks (DSB), promoting genomic instability and tumour heterogeneity. The single-stranded DNA cytosine deaminase APOBEC3B (A3B) serves as a co-activator of ER and is implicated in inducing DSBs at transcriptional enhancers regulated by ER. Using whole-genome sequencing in an engineered cell model lacking base excision repair (BER) function, we demonstrate that A3B preferentially targets transcriptionally active regulatory regions in an R-loop-dependent manner. Strand-specific DNA:RNA immunoprecipitation sequencing (ssDRIP-seq) and ssDNA-associated protein immunoprecipitation sequencing (SPI-seq) confirm that A3B binds to and deaminates ssDNA within R-loops, a process facilitated by ER transactivation. Furthermore, BER-mediated processing of A3B-induced uracil bases contributes to the formation of R-loop-associated DSBs, which are essential for ER-regulated gene activation. These findings establish a role for A3B in R-loop homeostasis and transcriptional regulation, with implications for understanding ER-driven genomic instability and potential therapeutic targeting of A3B.

Indexed as

Cytidine DeaminaseEnhancer Elements, GeneticMinor Histocompatibility AntigensReceptors, EstrogenR-Loop StructuresDNA Breaks, Double-StrandedDNA, Single-StrandedExcision RepairHumansTranscriptional ActivationAPOBEC3B protein, humanCytidine DeaminaseDNA, Single-StrandedMinor Histocompatibility AntigensReceptors, Estrogen

Identifiers

PMID41702955
PMCPMC13031881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.